Clinical Trial Update: A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial update of experimental medication BMS-986036 in adults with nonalcoholic steatohepatitis and stage 3 liver fibrosis; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• BMS-986036

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED | Results posted: 2022-09-09